KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Cash & Current Investments (2016 - 2025)

Gsk (GSK) has 7 years of Cash & Current Investments data on record, last reported at $3.8 billion in Q4 2023.

  • For Q4 2023, Cash & Current Investments fell 17.09% year-over-year to $3.8 billion; the TTM value through Dec 2023 reached $3.8 billion, down 17.09%, while the annual FY2023 figure was $3.8 billion, 21.25% down from the prior year.
  • Cash & Current Investments reached $3.8 billion in Q4 2023 per GSK's latest filing, down from $4.6 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $8.3 billion in Q4 2020 and bottomed at $3.8 billion in Q4 2023.
  • Average Cash & Current Investments over 4 years is $5.8 billion, with a median of $5.6 billion recorded in 2019.
  • Peak YoY movement for Cash & Current Investments: increased 29.46% in 2019, then decreased 17.09% in 2023.
  • A 4-year view of Cash & Current Investments shows it stood at $6.6 billion in 2019, then increased by 26.01% to $8.3 billion in 2020, then plummeted by 44.76% to $4.6 billion in 2022, then fell by 17.09% to $3.8 billion in 2023.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $3.8 billion in Q4 2023, $4.6 billion in Q4 2022, and $8.3 billion in Q4 2020.